Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
The energy giant reported industry-leading earnings and cash flow, driven by record production and deep cost cuts, while returning billions to shareholders and outlining an ambitious growth plan through 2030.
Nvidia's reported plan for a massive $100 billion investment in OpenAI is encountering significant internal resistance, according to a Wall Street Journal report, casting doubt on one of the most anticipated partnerships in the AI arms race and unsettling markets.
CFOs are no longer just funders of AI experiments but central architects of its enterprise-wide deployment, navigating a critical shift from promise to production.
Once considered a win-win solution, transforming closed landfills into solar farms faces a complex reality of high costs, regulatory hurdles, and site-specific challenges, even as demand for clean energy and affordable power surges.
The death of Jose 'Gonzalito' Sanchez, second-in-command of Colombia's largest criminal syndicate, in a boating accident raises immediate questions about the stability of ongoing government negotiations aimed at ending decades of conflict.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Rosenblatt Securities raised its rating on cybersecurity firm Fortinet ahead of its Q4 earnings, citing a favorable hardware refresh cycle, effective sales strategies, and supportive tax incentives as key growth drivers.
Investment firm William Blair has initiated coverage on Rambus Inc. with an 'Outperform' rating, highlighting the chip designer's dominant market share in interface circuits and its strategic positioning to capitalize on surging demand from AI data centers and server DRAM upgrades.
TD Cowen reaffirms its Buy rating on Dynatrace (DT) while adjusting its price target, anticipating stronger-than-expected performance driven by its new AI-powered observability platform, Dynatrace Intelligence.
Needham raises Nova Ltd. (NVMI) to Buy with a $500 price target, citing improving industry conditions and the company's strategic position in China's memory market. The upgrade follows a similar bullish move by Bank of America earlier in January.
A prolonged, nationwide internet blackout in Iran, imposed during recent unrest, has crippled businesses and severed global connections for millions, revealing the deep fragility of an economy already under strain.
The International Monetary Fund projects average growth in sub-Saharan Africa at 4.6% for the year, edging ahead of Asia's 4.1%, signaling a potential turning point driven by demographics but tempered by significant investment challenges.
Devon Energy announces plans to move its headquarters from Oklahoma City to Houston after finalizing its merger with Coterra Energy, while pledging to retain a substantial operational footprint in its longtime home state.
The Invesco NASDAQ-100 Equal Weight ETF (QQEW) has executed a dramatic portfolio shift, halving its holdings from 101 to 50 companies. This strategic pivot from pure equal-weighting to a quality-filtered approach aims to mitigate the risks of extreme concentration in the tech-heavy index while maintaining its core diversification ethos.
Hilton is deepening its investment in Utah's premier Deer Valley Resort with a new Waldorf Astoria hotel and branded residences, signaling a major push into high-end, experience-driven mountain hospitality as competition for affluent travelers intensifies.
